Edition:
United Kingdom

Healthcare

UPDATE 1-Edwards Lifesciences, Medtronic heart valves win U.S. approval for expanded use

Aug 16 Heart valve systems from Edwards Lifesciences Corp and Medtronic Plc have been approved for use in a condition that restricts blood flow from the heart in patients at low-risk of death linked to open-heart surgeries, the U.S. FDA said on Friday.

16 Aug 2019

UPDATE 2-Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Aug 16 Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year.

16 Aug 2019

UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr

Aug 16 AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.

16 Aug 2019

UPDATE 2-FDA approves Celgene's bone marrow cancer treatment

Aug 16 The U.S. Food and Drug Administration on Friday approved Celgene Corp's Inrebic to treat certain rare forms of bone marrow cancer called myelofibrosis, making it the second approved drug to treat the disease.

16 Aug 2019

Edwards Lifesciences, Medtronic heart valves win FDA approval for expanded use

Aug 16 Heart valve systems from Edwards Lifesciences Corp and Medtronic Plc have been approved for use in a condition that restricts blood flow from the heart in patients at low-risk of death linked to open-heart surgeries, the FDA said on Friday.

16 Aug 2019
Healthcare
GlaxoSmithKline PLC 1,658.00 +0.75%
AstraZeneca PLC 7,256.00 +0.36%
Smith & Nephew PLC 1,897.50 +0.93%

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.